MarketFriction

Themis Medicare Ltd

NSE THEMISMED · BSE 530199 · Pharmaceuticals
₹113.19 -2.81%
NSE close2026-10-01
52 week range64.95 - 147.00
Market cap₹1,103 Cr.
Price band 20% Delivery 46.1%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales105839812311794729878907787
Expenses927489941008879108818073139
Operating Profit128929176-8-10-3104-52
OPM %12%10%10%24%15%6%-11%-10%-4.0%11%4.9%-60%
Other Income76576121561197
Interest232223223333
Depreciation333223333333
Profit before tax148931182-11-14-310939
Tax %19%10%24%21%20%69%-13%1%5%3%2%36%
Net Profit117725141-10-14-410925
EPS in Rs1.230.800.722.681.550.06-1.05-1.54-0.391.100.972.67
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales232217210184202231395354382406342332
Expenses194184184181166181299287330356342374
Operating Profit38332523649966752490-42
OPM %16%15%12%1.2%18%21%24%19%13%12%0.1%-13%
Other Income346512131825241123118
Interest1212121213139109101111
Depreciation127788991012101010
Profit before tax171811-13274195735340255
Tax %11%9%1%-15%8%14%23%22%19%25%40%
Net Profit161611-11253673574430140
EPS in Rs1.911.771.23-1.172.703.887.926.184.733.240.124.35
Dividend Payout %9%0%0%0%6%11%6%8%11%15%404%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth4%8%-1%-13%
Compounded Profit Growth-20%-46%-69%-321%
Stock Price CAGR7%4%-13%-8%
Return on Equity11%12%6%0%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital899999999999
Reserves5166143160149174209278330368393389
Borrowings1401288280821008780929683100
Other Liabilities7773545674676561829310299
Total Liabilities277275289305314350371428514566588598
Fixed Assets122117124126123116133144162168172167
CWIP469228233332
Investments56232427354556708995109
Other Assets146146133153162191191225279307318320
Total Assets277275289305314350371428514566588598
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1926-281105734162235-3
Cash from Investing Activity-6-7-4-0-4-5-16-16-24-16-12-3
Cash from Financing Activity-18-135-9-107-26-180-9-264
Net Cash Flow-55-0-1-32161-8-3-3-2
Free Cash Flow1318-755-53915-13421-8
CFO/OP101%73%-5%29%490%2%115%55%48%60%93%782%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days82758112014518612393149170159190
Inventory Days246243250253287315272150213188233229
Days Payable23714516315618717114379123126142143
Cash Conversion Cycle91172168216244330251164239232250275
Working Capital Days-20-17-1619-1375172110114121138
ROCE %9%15%13%10%-1%15%18%30%20%14%10%3%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters67.16%67.16%67.15%67.15%67.15%67.15%67.15%67.15%67.15%67.10%67.10%67.10%
FIIs0.05%0.01%0.03%0.05%0.10%0.10%0.14%0.09%0.06%0.05%0.11%0.01%
DIIs0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public32.77%32.82%32.81%32.79%32.74%32.75%32.70%32.75%32.77%32.84%32.78%32.87%
No. of Shareholders6,97011,24411,29511,32214,27017,77317,88919,33522,49022,57621,81821,267

Fundamentals

Market Cap₹ 1,103 Cr.
Current Price₹ 120
Book Value₹ 43.3
ROCE2.74 %
ROE0.41 %
Dividend Yield0.42 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)-13%
Compounded Profit Growth (TTM)-321%
Consolidated figures.
Valuation
Market capRs 1,042 Cr
Enterprise valueRs 1,133 Cr
P/E (TTM)26.08x
Price to book2.62x
Price to sales3.14x
EV / EBITDA14.90x
EV / EBIT17.23x
EV / sales3.42x
Earnings yield3.83%
Dividend yield0.44%
P/E, 3-year average208.45x
P/B, 3-year average3.40x
P/E, 5-year average125.69x
P/B, 5-year average2.17x
Profitability
Operating margin (excl. other income)0.12%
Operating margin (incl. other income)6.70%
EBITDA margin22.95%
Pre-tax margin16.47%
Net profit margin12.05%
Net margin, latest quarter28.30%
ROE0.28%
ROCE2.56%
ROA0.19%
ROE, 3-year average6.69%
ROCE, 3-year average8.94%
ROA, 3-year average4.47%
ROE, 5-year average13.41%
ROCE, 5-year average15.65%
ROA, 5-year average8.75%
ROIC (approx.)8.01%
Tax rate40.41%
Other income / net worth5.66%
Growth
Sales growth (latest year)-15.60%
Profit growth (latest year)-96.18%
Sales CAGR, 3 years-1.15%
Sales CAGR, 5 years8.21%
Profit CAGR, 3 years-72.84%
Profit CAGR, 5 years-49.78%
Sales growth QoQ13.63%
Profit growth QoQ176.83%
Sales growth YoY (latest quarter)-10.88%
Per share
EPS (TTM)Rs 4.34
EPS (latest year)Rs 0.12
EPS (latest quarter)Rs 2.67
EPS, 3-year averageRs 2.70
EPS, 5-year averageRs 29.83
Book value per shareRs 43.28
Sales per shareRs 36.01
Cash flow per shareRs -0.35
Free cash flow per shareRs -0.87
Dividend per share (latest year)Rs 0.50
Dividend per share, 3-year averageRs 0.50
Dividend per share, 5-year averageRs 2.30
Dividends
Dividend payout403.51%
Dividend payout, 3-year average143.17%
Dividend payout, 5-year average88.78%
Efficiency
Asset turnover0.57x
Fixed asset turnover2.06x
Inventory turnover1.99x
Inventory days183 days
Debtor days190 days
Debtors turnover1.92x
Creditor days143 days
Cash conversion cycle275 days
Working capital days138 days
Leverage
Total debtRs 100 Cr
Cash and bankRs 9 Cr
Net debtRs 91 Cr
Debt to equity0.25x
Net debt / EBITDA1.20x
Interest coverage5.88x
Current ratio (filing 2026-03-31)1.84x
Quick ratio (filing 2026-03-31)1.35x
Trade payables (filing 2026-03-31)Rs 51 Cr
Owners' fund to total sources66.66%
Debt to assets16.74%
Cash flow
Cash from Operating Activity (latest year)Rs -3 Cr
Cash from Investing Activity (latest year)Rs -3 Cr
Cash from Financing Activity (latest year)Rs 4 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs -8 Cr
FCFE (approx.: FCF + change in debt)Rs 9 Cr
Cash from ops / profit, 5 years0.51x
Statement figures
Net sales (TTM)Rs 332 Cr
Net sales (latest year)Rs 342 Cr
Sales (latest quarter)Rs 87 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
Operating profit (latest quarter)Rs -52 Cr
Other income (TTM)Rs 118 Cr
EBITDA (TTM)Rs 76 Cr
PBDT (TTM)Rs 65 Cr
Profit before tax (TTM)Rs 55 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 40 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 25 Cr
Depreciation (TTM)Rs 10 Cr
Depreciation (latest quarter)Rs 3 Cr
Interest (TTM)Rs 11 Cr
Cost of goods sold (latest year)Rs 161 Cr
Total expenditure (latest year)Rs 342 Cr
Total income (latest year)Rs 365 Cr
Share capitalRs 9 Cr
ReservesRs 389 Cr
Shareholders' fundsRs 399 Cr
Total assetsRs 598 Cr
Net blockRs 167 Cr
Capital work in progressRs 2 Cr
InvestmentsRs 109 Cr
ReceivablesRs 178 Cr
InventoryRs 81 Cr
Other liabilitiesRs 99 Cr
Shares outstanding (crore)9.21
Ownership
Promoter holding67.10% (-0.05 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 26.1 is at the 56th percentile of its own 7.4-year range (median 25.4, low 9.4, high 61.9).
P/B 2.62 is at the 43th percentile (median 2.91).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodTHEMISMEDNifty 50Difference
1 week-4.2%-2.8% -1.4 pts
1 month-8.4%-6.8% -1.6 pts
3 months-4.6%-7.6% +3.1 pts
6 months+71.3%+0.4% +70.9 pts
1 year-20.5%-9.9% -10.6 pts
2 years-59.2%-13.6% -45.6 pts
3 years-37.4%+14.2% -51.6 pts
5 years+14.1%+27.9% -13.8 pts
1 mutual fund schemes hold about ₹0 Cr. Over three months 1 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.02%0 +16%

Red flags

F-score 2 of 8
explainLow interest cover Interest cover 1.2x in 2026
lookProfit leans on other income Other income was 1168% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹87 Cr -11.2% vs Jun 2025. Net profit ₹25 Cr +278.6%.
Against our estimate for Jun 2026: sales -12.4%, profit +741.5% beat. Our estimate for Sep 2026: sales Rs 76 Cr, profit Rs 9 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-09-23Dividend - Re 0.50 Per Share
2025-09-04Dividend - Re 0.50 Per Share
2024-07-12Annual General Meeting/Dividend - Rs 0.50 Per Share
2023-10-10Face Value Split (Sub-Division) - From Rs 10/- Per Share To Re 1/- Per Share0.1000
2023-09-01Annual General Meeting/Dividend - Rs 5 Per Share
2022-09-08Annual General Meeting/Dividend - Rs 5 Per Share
2021-09-08 Annual General Meeting/Dividend - Rs 4.30 Per Share
2020-09-17 Annual General Meeting/Dividend - Rs 1.75 Per Share
2019-08-19 Annual General Meeting
2018-08-30 Annual General Meeting
2017-09-19 Annual General Meeting
2016-09-06 Annual General Meeting
2015-09-11 Annual General Meeting
2014-09-19Annual General Meeting
2013-08-21Annual General Meeting
2011-07-20Annual General Meeting And Dividend Rs.3/- Per Share
2010-06-16Annual General Meeting And Dividend Rs.3/- Per Share
2009-12-01Annual General Meeting
2008-08-01Agm/Dividend - 25%
2007-09-14Agm/Dividend-20%
DateTypeWhat it says
2026-10-01Shareholder meetingVoting results of 56th AGM.
2026-09-30Shareholder meetingScrutinizers Report and voting results of Annual General Meeting held on September 30, 2026
2026-09-30Credit Rating- RevisionCredit Rating- Revision
2026-09-30Amendment to AOA/MOAThe Amendment to AOA/MOA of the company.
2026-09-30Amendment to AOA/MOAThe Amendment to AOA/MOA of the company.
2026-09-30Shareholder meetingProceedings of Annual General Meeting held on September 30, 2025
2026-09-24General UpdatesThe Withdrawal of proposed Preferential Issue of 45,95,795 convertible equity warrants.
2026-09-18General UpdatesGeneral Updates of Record Date for the Dividend for FY 2025-26.
2026-09-08Shareholder meetingNotice of 56th Annual General Meeting to be held on September 30, 2026
2026-09-07Volume querySignificant increase in volume has been observed in Themis Medicare Limited. The Exchange, in order to ensure that investors have latest relevant info...
2026-09-07Volume querySignificant increase in volume has been observed in Themis Medicare Limited. The Exchange, in order to ensure that investors have latest relevant info...
2026-08-17General UpdatesGeneral Updates -Change Of Company Secretary / Compliance Officers E-Mail ID and updation of E-Mail Id of RTA,
2026-08-13ResignationResignation of Director/KMP/SMP
2026-08-13ResignationResignation of Director/KMP/SMP
2026-08-13ResignationResignation of Director/KMP/SMP
2026-08-13ResignationResignation of Director/KMP/SMP
2026-08-13Investor PresentationInvestor Presentation
2026-08-13General UpdatesGeneral Updates
2026-08-13AppointmentAppointment of Mr. Suresh Savaliya as Company Secretary & Compliance Officer of the company w.e.f. August 13, 2026.
2026-08-13ResignationResignation of Mr. Nagraj Mogaveera as Company Secretary & Compliance Officer of the company w.e.f. August 13, 2026.
2026-08-13Board meeting outcomeThemis Medicare Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended Jun 30, 2026.
2026-06-23Volume querySignificant increase in volume has been observed in Themis Medicare Limited. The Exchange, in order to ensure that investors have latest relevant info...
2026-06-22Volume querySignificant increase in volume has been observed in Themis Medicare Limited. The Exchange, in order to ensure that investors have latest relevant info...
2026-05-28Investor PresentationInvestor Presentation
2026-05-28Board meeting outcomeThemis Medicare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Themis Medicare Ltd?

Themis Medicare Ltd (THEMISMED) has a market capitalisation of Rs 1,103 Cr. at the 2026-10-01 close.

What were Themis Medicare Ltd's latest quarterly results?

In the Jun 2026 quarter, Themis Medicare Ltd sales was Rs 87 Cr (-11.2% vs Jun 2025) and net profit was Rs 25 Cr.

What is the 52-week high and low of Themis Medicare Ltd?

The 52-week high is Rs 147.00 and the 52-week low is Rs 64.95.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03